GlassScriptPhysician profile
Jeffrey A Medlock
NPI 1689692360
$2,971.80
in general payments reported to CMS, 2019-2025
25 companies · $715 in 2025
The $715 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $355 · 2021: $439 · 2022: $208 · 2023: $510 · 2024: $490 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $570.12 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $551.36 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.39 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $214.40 | 2020-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $193.35 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $189.94 | 2020-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.60 | 2025 | Caplyta |
| Allergan, INC. | $124.51 | 2019-2020 | |
| Almatica Pharma LLC | $103.02 | 2023-2024 | Loreev Xr |
| Lilly USA, LLC | $99.23 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $91.07 | 2020-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $72.54 | 2022-2024 | Rexulti |
| Abbott Laboratories | $53.42 | 2021-2022 | |
| Exact Sciences Corporation | $47.54 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $28.52 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27.56 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $24.59 | 2019 | |
| Amarin Pharma, INC. | $18.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.55 | 2020 | |
| Verona Pharma, INC. | $17.26 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2021 | |
| Genentech USA, INC. | $14.63 | 2020 | |
| Merck Sharp & Dohme LLC | $14.41 | 2020 | |
| Alnylam Pharmaceuticals INC. | $13.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Medlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.